-
Dec 4, 2024 | 
nature.com | Yekaterina Shulgina |Marena Trinidad |Conner Langeberg |Hunter Nisonoff |Seyone Chithrananda |Petr Skopintsev | +7 more
AbstractStructured RNA lies at the heart of many central biological processes, from gene expression to catalysis. RNA structure prediction is not yet possible due to a lack of high-quality reference data associated with organismal phenotypes that could inform RNA function. We present GARNET (Gtdb Acquired RNa with Environmental Temperatures), a new database for RNA structural and functional analysis anchored to the Genome Taxonomy Database (GTDB).
-
Nov 26, 2024 | 
technewstube.com | Jennifer Doudna
Tech News Tube is a real time news feed of the latest technology news headlines.Follow all of the top tech sites in one place, on the web or your mobile device.
-
Nov 26, 2024 | 
wired.com | Jennifer Doudna
In 2025, we will see AI and machine learning begin to amplify the impact of Crispr genome editing in medicine, agriculture, climate change, and the basic research that underpins these fields. It’s worth saying upfront that the field of AI is awash with big promises like this. With any major new technological advance there is always a hype cycle, and we are in one now.
-
Nov 26, 2024 | 
flipboard.com | Jennifer Doudna
13 hours agoOne fan has helped Kylie Kelce deliver the ultimate comeback joke to her husband Jason. On Friday, Nov. 22, the couple announced they are expecting their fourth child—and their fourth daughter—in an Instagram pregnancy announcement. The two share daughters Wyatt, 5, Elliotte, 3, and Bennett, 21 …
-
Feb 20, 2024 | 
shepherd.com | Kevin P. Davies |Jennifer Doudna |Samuel H. Sternberg |Henry T. Greely
A Crack in Creation was the first mainstream book that conveyed the extraordinary potential and ethical peril of the new genome editing technology, CRISPR. And who better to write it than the scientist who co-developed the “genetic scissors”, Professor Jennifer Doudna (who won the Nobel Prize three years later).
-
Jan 23, 2024 | 
biorxiv.org | Jason L. Nomburg |Nathan Price |Jennifer Doudna
AbstractRapid virus evolution generates proteins essential to infectivity and replication but with unknown function due to extreme sequence divergence. Using a database of 67,715 newly predicted protein structures from 4,463 eukaryotic viral species, we found that 62% of viral proteins are evolutionarily young and lack homologs in the Alphafold database.
-
Jan 8, 2024 | 
wired.com | Jennifer Doudna
At the end of 2023, we witnessed an important moment in the history of medicine: For the first time, the US Food and Drug Administration approved a therapy that uses Crispr gene editing. This new therapy was developed by Crispr Therapeutics and Vertex Pharmaceuticals to treat sickle cell disease, an ailment caused by a single-letter mutation in the genetic code that has been long understood but was neglected by the research community for decades.
-
Dec 24, 2023 | 
wired.jp | Jennifer Doudna
世界中のビジョナリーや起業家、ビッグシンカーがキーワードを掲げ、2024年の最重要パラダイムを網羅した恒例の総力特集「THE WORLD IN 2024」。ゲノム編集技術「CRISPR-Cas9」でノーベル化学賞を受賞したジェニファー・ダウドナは、新たな治療法の開発の先に、その低コスト化と普及の道筋を見据えている。 2023年の終盤に、わたしたちは医学の歴史において重要な瞬間を目撃した。ゲノム編集技術「CRISPR」を活用した治療法が初めて、米食品医薬品局（FDA）の認可を受けたのだ。鎌状赤血球症に対するこの新しい治療法は、CRISPR TherapeuticsとVertex Pharmaceuticalsにより開発された。鎌状赤血球症は1塩基変異によって生じる疾患で、ずいぶん前に判明していたものの、研究が進まないまま何十年ものあいだ見過ごされていたのだ。...
-
Nov 2, 2023 | 
issues.org | Tom Burroughs |Jennifer Doudna |William S. Kearney
Big First for Gene Editing November 2, 2023 The FDA appears ready to approve the first commercial use of gene editing to treat a disease. In this case, a drug company is seeking to use the gene-editing tool CRISPR to treat sickle cell disease, an inherited blood disorder. “It’s extraordinary to think that we’re on the verge of an approval of the first CRISPR therapy,” Jennifer Doudna, a CRISPR codiscoverer, tells NPR.
-
Oct 18, 2023 | 02390-6/abstract&sz=64)
jbc.org | Christopher Carlson |Alison Ciling |Jennifer Doudna
AbstractThe Nucleocapsid (N) protein of SARS-CoV-2 compacts the RNA genome into viral ribonucleoprotein (vRNP) complexes within virions. Assembly of vRNPs is inhibited by phosphorylation of the N protein SR region. Several SARS-CoV-2 variants of concern carry N protein mutations that reduce phosphorylation and enhance the efficiency of viral packaging.
